• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » IMS Health forecast: Global pharmaceutical market poised for growth in 2011 to $880 billion

IMS Health forecast: Global pharmaceutical market poised for growth in 2011 to $880 billion

October 25, 2010
CenterWatch Staff

Robust pharmaceutical spending in 17 emerging countries led by China, and those governments making more treatment options available to their citizens, will offset patent losses and slow growth in the United States pharmaceutical market, according to a forecast by IMS Health.

IMS, an industry data company, expects the global drug market to grow 5% to 7% in 2011 to $880 billion. Drug sales for 2010 are expected to rise 4% to 5%.

Next year’s outlook is based, in part, on China’s anticipated strong growth—25% to 27% to $50 billion—making it the world’s third largest market for prescription drugs, according to IMS projections.

The United States, far and away the leader in pharmaceutical sales, is expected to reach $320 billion to $330 billion in 2011, up about 4% from the $310 billion forecast for this year, not including the impact of off-invoice discounts or rebates. Prescription sales in Canada and in Europe’s five largest markets—Germany, France, Italy, Spain and the United Kingdom—will inch up 1% to 3% next year, according to the IMS forecast.

The lower growth in Europe and the U.S. is also due to insurers and government health programs wanting to hold down spending on prescription drugs. Strategies include greater pre-authorizations for more medications, higher copayments and a reduction in reimbursement levels in some European countries.

“In 2011, we will see the loss of exclusivity for some iconic brands and a promising new wave of innovation,” said Murray Aitken, IMS senior vice president. “It also will be a critical year for gauging how healthcare reform initiatives in key markets evolve and play out amid the expected macro-economic recovery.” 

Next year will mark the introduction and uptake of new drugs including innovative treatment options for stroke prevention, melanoma, breast cancer and hepatitis C, and the first oral medication to treat multiple sclerosis. IMS estimates five potential blockbuster drugs—each with more than $1 billion in annual peak sales—are expected to be approved and launched globally by the end of 2011.

On the down side, patents for drugs with sales of more than $30 billion will expire in 2011, including four medications that accounted for more than 93 million prescriptions dispensed in the past 12 months and $17 billion in total sales. They face low-cost, generic competition in the U.S. and other major markets.

“No doubt big pharma will look to emerging markets for opportunities to offset the loss of revenue to generic competition, but it won’t be easily done,” concluded the Burrill Report in its analysis of the IMS Health forecast. “The pricing pressures and generic competition that is new in developed markets is a fact of life in the emerging countries.”

—Ronald Rosenberg

 

    Upcoming Events

    • 16Oct

      MAGI@home Clinical Research Conference 2023

    • 25Oct

      2023 WCG Patient Forum

    • 26Oct

      FDA in 2024: What to Expect in an Election Year

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Donna Snyder

      New WCG Executive Physician Outlines Goals for Clinical Research

    • Hand Shake at Meeting

      Partnership to Bolster Trials in Low Resource Regions Kicks Off

    • Guidelines-360x240.png

      Major Industry Groups Offer Feedback on ICH’s E6(R3) Guidelines

    • AsktheExpertsBadge-360x240.png

      Ask the Experts: Monitoring

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing